Replies to post #796818 on NorthWest Biotherapeutics Inc (NWBO)

[notbrad]

They are family.

[seekinganswers]

Why is that interesting? DCVax L was developed by UCLA via Liau and Prins ... NWBO licenses it from them.
DCVax L is the ONLY product that NWBO licenses from UCLA.

"DCVax (specifically DCVax-L) and ATL-DC are both autologous tumor lysate-pulsed dendritic cell (DC) vaccines targeting glioblastoma (GBM), but they are distinct products developed and manufactured by separate entities, with no direct equivalence or shared production for their respective trials.Key Differences:Developer and Ownership:DCVax-L is the proprietary product of Northwest Biotherapeutics (NWBO), a Maryland-based biotech company. It's their lead candidate in a Phase 3 trial (NCT00045968) for newly diagnosed and recurrent GBM, involving over 300 patients across multiple sites.

ATL-DC is an investigational vaccine developed by researchers at UCLA (primarily through the lab of Dr. Robert Prins and collaborators like Dr. Linda Liau), under UCLA's Specialized Programs of Research Excellence (SPORE) in brain cancer. It's used in smaller Phase 1 trials, such as one combining it with pembrolizumab (Keytruda) for recurrent, surgically accessible GBM (NCT04201873)."